Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003

ABSTRACT We conducted population-based surveillance for Candida bloodstream infections in Spain to determine its incidence, the extent of antifungal resistance, and risk factors for mortality. A case was defined as the first positive blood culture for any Candida spp. in a resident of Barcelona, from 1 January 2002 to 31 December 2003. We defined early mortality as occurring between days 3 to 7 after candidemia and late mortality as occurring between days 8 to 30. We detected 345 cases of candidemia, for an average annual incidence of 4.3 cases/100,000 population, 0.53 cases/1,000 hospital discharges, and 0.73 cases/10,000 patient-days. Outpatients comprised 11% of the cases, and 89% had a central venous catheter (CVC) at diagnosis. Overall mortality was 44%. Candida albicans was the most frequent species (51% of cases), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8%), Candida krusei (4%), and other species (3%). Twenty-four isolates (7%) had decreased susceptibility to fluconazole (MIC ≥ 16 μg/ml). On multivariable analysis, early death was independently associated with hematological malignancy (odds ratio [OR], 3.5; 95% confidence interval [CI], 1.1 to 10.4). Treatment with antifungals (OR, 0.05; 95% CI, 0.01 to 0.2) and removal of CVCs (OR, 0.3; 95% CI, 0.1 to 0.9) were protective factors for early death. Receiving adequate treatment, defined as having CVCs removed and administration of an antifungal medication (OR, 0.2; 95% CI, 0.08 to 0.8), was associated with lower odds of late mortality; intubation (OR, 7.5; 95% CI, 2.6 to 21.1) was associated with higher odds. The incidence of candidemia and prevalence of fluconazole resistance are similar to other European countries, indicating that routine antifungal susceptibility testing is not warranted. Antifungal medication and catheter removal are critical in preventing mortality.

[1]  Patrick R. Murray,et al.  Candida, Cryptococcus, and other yeasts of medical importance. , 2006 .

[2]  J. A. J. W. Kluytmans,et al.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  M. Pfaller,et al.  Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 , 2004, Journal of Clinical Microbiology.

[4]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[5]  D. Pittet,et al.  Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Pfaller,et al.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  D. Pittet,et al.  Management of candidiasis Management of Candida species infections in critically ill patients , 2003 .

[9]  E. Baron,et al.  Comparison of the Susceptibilities of Candida spp. to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion , 2003, Journal of Clinical Microbiology.

[10]  A. Tortorano,et al.  The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. , 2003, The Journal of antimicrobial chemotherapy.

[11]  D. Denning,et al.  Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts , 2003 .

[12]  V. Anttila,et al.  Candidemia in Finland, 1995–1999 , 2003, Emerging infectious diseases.

[13]  W. Gransden,et al.  Management and outcome of bloodstream infections due to Candida species in England and Wales. , 2003, The Journal of hospital infection.

[14]  J. L. López Sastre,et al.  Neonatal Invasive Candidiasis: A Prospective Multicenter Study of 118 Cases , 2003, American journal of perinatology.

[15]  M. Fariñas,et al.  Candidemia in a Tertiary Care Hospital: Epidemiology and Factors Influencing Mortality , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  J. L. López Sastre,et al.  Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. , 2003, American journal of perinatology.

[17]  D. Pittet,et al.  Management of Candida species infections in critically ill patients. , 2003, The Lancet. Infectious diseases.

[18]  D. Pittet,et al.  Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.

[19]  J. Pemán,et al.  Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for Death , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  M. Pfaller,et al.  Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.

[21]  L. R. Ásmundsdóttir,et al.  Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland , 2002, Journal of Clinical Microbiology.

[22]  R. Gaynes,et al.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Tortorano,et al.  European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.

[24]  H. Richet,et al.  Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  M. Pfaller,et al.  Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study , 2002, Journal of Clinical Microbiology.

[26]  J. Pemán,et al.  [Epidemiology of candidemia in Spain - Multicenter study] , 2002, Revista iberoamericana de micologia.

[27]  D. Sanglard,et al.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.

[28]  E. Anaissie,et al.  Revisiting the source of candidemia: skin or gut? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[30]  L. Mermel,et al.  Guidelines for the Management of Intravascular Catheter-Related Infections , 2001, Infection Control & Hospital Epidemiology.

[31]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[32]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[33]  R. Pinner,et al.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  B. Lebeau,et al.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Cisterna,et al.  [Description of 165 episodes of fungemia: A multicenter study.]. , 1999, Revista iberoamericana de micologia.

[38]  M. Steinbakk,et al.  Constant Low Rate of Fungemia in Norway, 1991 to 1996 , 1998, Journal of Clinical Microbiology.

[39]  E. Kossoff,et al.  Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. , 1998, The Pediatric infectious disease journal.

[40]  Ronald N. Jones,et al.  National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. , 1998, Diagnostic microbiology and infectious disease.

[41]  M. White The contribution of fluconazole to the changing epidemiology of invasive candidal infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  E. Anaissie,et al.  The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. Sitges-Serra,et al.  Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.

[44]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[45]  J. Wingard,et al.  Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  M. Larocco,et al.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period , 1994, Antimicrobial Agents and Chemotherapy.

[47]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[48]  W J Martone,et al.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.

[49]  R. Chang,et al.  Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure , 1988, Intensive Care Medicine.

[50]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.